28.03.2020, 19:14:23
Cytuję fragment artykułu z ostatniej Prostatopedii.
Dr. Oliver Sartor: Potential Link between COVID-19 and Prostate Cancer?
Is there a possible link between prostate cancer and COVID-19?
One of the receptors that the virus binds to is TMPRSS2. TMPRSS2 is well known in prostate cancer circles because it is expressed in prostate cancer and is part of a translocation, the TMPRSS2-ERG translocation, or TMPRSS2-S family translocation, which occurs in about half of men. TMPRSS2 is also expressed in the lung. You may have read that there is a predilection toward male death in this disease. The infection rate doesn't seem to vary particularly, although men may have a slightly higher infection rate, but the death rate and severe COVID-19 disease rate is worse in men.
TMPRSS2 in the lung can be downregulated, or reduced or suppressed, by androgen deprivation therapy (ADT). Alexander Meisel, from the University Hospital in Zurich, brought this idea to Bayer, who has a drug called Nubeqa (darolutamide). This drug can downregulate the androgen receptor and is reversible. Bayer is going to do a clinical trial in hospitalized COVID-19 patients using Nubeqa (darolutamide)
There are other agents that could be used in this setting. Some may be as simple as Casodex (bicalutamide). This is not an endorsement for people to start taking Casodex (bicalutamide), but a clinical trial will be done on ADT. Because the TMPRSS2 is a receptor for the virus and is expressed within lung tissue, that may explain part of the male predilection for severe COVID-19 illness.
[i][Prostatepedia’s Note: This means that there is a chance that men on Androgen Deprivation Therapy are protected slightly from COVID-19 compared to men their age not on ADT. Clinical Trials are underway; please do not rush to ask your doctor to prescribe ADT unless you are already in treatment. This is just a hypothesis and has not been shown to be true.]
[/i]
O co chodzi, w wielkim skrócie:
Dr. Oliver Sartor, zapytany, czy istnieje związek między koronawirusem a rakiem prostaty,
wyjaśnia, że wirus ten łączy się z pewnym receptorem na powierzchni błony komórki, znanym z badań nad rakiem prostaty. Receptor ten występuje aż u połowy mężczyzn, co tłumaczy większą śmiertelność mężczyzn z powodu koronowirusa.
Co ważne - doktor ten stawia hipotezę, że mężczyźni na hormonoterapii (również na bikalutamidzie) są z powodu zablokowania tego receptora(?) w jakimś sensie chronieni przed koronawirusem.
Byłaby to przynajmniej jedna dobra strona hormonoterapii.
Dr. Oliver Sartor: Potential Link between COVID-19 and Prostate Cancer?
Is there a possible link between prostate cancer and COVID-19?
One of the receptors that the virus binds to is TMPRSS2. TMPRSS2 is well known in prostate cancer circles because it is expressed in prostate cancer and is part of a translocation, the TMPRSS2-ERG translocation, or TMPRSS2-S family translocation, which occurs in about half of men. TMPRSS2 is also expressed in the lung. You may have read that there is a predilection toward male death in this disease. The infection rate doesn't seem to vary particularly, although men may have a slightly higher infection rate, but the death rate and severe COVID-19 disease rate is worse in men.
TMPRSS2 in the lung can be downregulated, or reduced or suppressed, by androgen deprivation therapy (ADT). Alexander Meisel, from the University Hospital in Zurich, brought this idea to Bayer, who has a drug called Nubeqa (darolutamide). This drug can downregulate the androgen receptor and is reversible. Bayer is going to do a clinical trial in hospitalized COVID-19 patients using Nubeqa (darolutamide)
There are other agents that could be used in this setting. Some may be as simple as Casodex (bicalutamide). This is not an endorsement for people to start taking Casodex (bicalutamide), but a clinical trial will be done on ADT. Because the TMPRSS2 is a receptor for the virus and is expressed within lung tissue, that may explain part of the male predilection for severe COVID-19 illness.
[i][Prostatepedia’s Note: This means that there is a chance that men on Androgen Deprivation Therapy are protected slightly from COVID-19 compared to men their age not on ADT. Clinical Trials are underway; please do not rush to ask your doctor to prescribe ADT unless you are already in treatment. This is just a hypothesis and has not been shown to be true.]
[/i]
O co chodzi, w wielkim skrócie:
Dr. Oliver Sartor, zapytany, czy istnieje związek między koronawirusem a rakiem prostaty,
wyjaśnia, że wirus ten łączy się z pewnym receptorem na powierzchni błony komórki, znanym z badań nad rakiem prostaty. Receptor ten występuje aż u połowy mężczyzn, co tłumaczy większą śmiertelność mężczyzn z powodu koronowirusa.
Co ważne - doktor ten stawia hipotezę, że mężczyźni na hormonoterapii (również na bikalutamidzie) są z powodu zablokowania tego receptora(?) w jakimś sensie chronieni przed koronawirusem.
Byłaby to przynajmniej jedna dobra strona hormonoterapii.